FindTrial
Sign In

Estimation of preference for selection of oral COVID-19 treatments

Estimation of preference for selection of oral COVID-19 treatments - Estimation of preference for selection of oral COVID-19 treatments

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000048518
Enrollment
11000
Registered
2022-08-02
Start date
2022-08-05
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

None listed

Sponsors

Shionogi & Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. General population: 10,000 people 2. People who have been infected with SARS-CoV-2: 1,000 people: 1,000 people (if the number of respondents does not reach the target number, those between 10 and 79 years old will be included).

Exclusion criteria

Exclusion criteria: People who stop responding to the survey (not considered as respondents)

Design outcomes

Primary

MeasureTime frame
Preference of factors about the oral COVID-19 treatments: dosage form and size, frequency of administration per day, number of drugs at once, number of days taking not to infect others from initiation of the treatment, developed company (domestic or foreign company), and out-of-pocket cost—

Countries

Japan

Contacts

Public ContactKenji Kurazono

Shionogi & Co., Ltd. Medical Affairs Dept.

kenji.kurazono@shionogi.co.jp06-6209-7412

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026